Crystalline amifostine compositions
US5591731A · kind A · utility
72Cited by
1References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 16, 1995 |
| Grant date | Jan 7, 1997 |
| Priority date | — |
| Expiry date | Feb 16, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/1651
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.